{"id":11238,"date":"2019-11-19T00:00:00","date_gmt":"2019-11-19T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/"},"modified":"2025-08-19T08:28:20","modified_gmt":"2025-08-19T13:28:20","slug":"approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2019\/11\/19\/approbation-du-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-les-patients-nouvellement-diagnostique-non-admissibles-a-une-greffe\/","title":{"rendered":"APPROBATION DU DARATUMUMAB EN ASSOCIATION AVEC LE L\u00c9NALIDOMIDE ET LA DEXAM\u00c9THASONE POUR LES PATIENTS NOUVELLEMENT DIAGNOSTIQU\u00c9 NON ADMISSIBLES \u00c0 UNE GREFFE"},"content":{"rendered":"<p>Le groupe Janssen Pharmaceutical Companies of Johnson &amp; Johnson a annonc\u00e9 que Sant\u00e9&nbsp;Canada a r\u00e9cemment approuv\u00e9, \u00e0 la suite d&rsquo;une \u00e9valuation prioritaire, DARZALEX<sup>\u00ae<\/sup>&nbsp;(daratumumab) en association avec le l\u00e9nalidomide et la dexam\u00e9thasone&nbsp;(Rd) pour le traitement des patients atteints d&rsquo;un my\u00e9lome multiple nouvellement diagnostiqu\u00e9 non admissibles \u00e0 une greffe autologue de cellules souches&nbsp;(GACS). L&rsquo;approbation se fonde sur les r\u00e9sultats de l&rsquo;\u00e9tude clinique de phase&nbsp;III&nbsp;MAIA, publi\u00e9e dans la revue&nbsp;<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=fr&amp;o=2625779-1&amp;h=686767432&amp;u=https%3A%2F%2Fwww.nejm.org%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1817249&amp;a=New%C2%A0England+Journal+of%C2%A0Medicine\" target=\"_blank\" rel=\"noopener\"><em>New&nbsp;England Journal of&nbsp;Medicine<\/em><\/a>; ceux-ci ont montr\u00e9 que l&rsquo;association DARZALEX<sup>\u00ae<\/sup>-Rd a r\u00e9duit le risque de progression de la maladie ou de d\u00e9c\u00e8s comparativement au traitement par le sch\u00e9ma&nbsp;Rd seul (r\u00e9duction du risque de 44&nbsp;%).<\/p>\n<p><a href=\"https:\/\/www.newswire.ca\/fr\/news-releases\/janssen-annonce-l-approbation-par-sante-canada-de-darzalex-r-daratumumab-en-association-avec-le-lenalidomide-et-la-dexamethasone-pour-le-traitement-des-patients-atteints-d-un-myelome-multiple-nouvellement-diagnostique-non-admissibles-a-une--894883253.html\" target=\"_blank\" rel=\"noopener\">Lire la suite<\/a>&#8230;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Le groupe Janssen Pharmaceutical Companies of Johnson &amp; Johnson a annonc\u00e9 que Sant\u00e9&nbsp;Canada a r\u00e9cemment approuv\u00e9, \u00e0 la suite d&rsquo;une \u00e9valuation prioritaire, DARZALEX\u00ae&nbsp;(daratumumab) en association avec le l\u00e9nalidomide et la dexam\u00e9thasone&nbsp;(Rd) pour le traitement des patients atteints d&rsquo;un my\u00e9lome multiple nouvellement diagnostiqu\u00e9 non admissibles \u00e0 une greffe autologue de cellules souches&nbsp;(GACS). L&rsquo;approbation se fonde sur [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11238","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11238"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11238\/revisions"}],"predecessor-version":[{"id":31321,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11238\/revisions\/31321"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}